Rein Therapeutics, Inc. (RNTX)

0.37 USD-8.00%
Gurus hold—none of the tracked superinvestors
Net buying (quarter)—latest quarter, superinvestors
Market Cap$31.7M
P/E (TTM)Price/Earnings: share price over annual profit — what you pay per $1 of earnings. Compare within the sector.LossDividend Yield: 0.00%

Rein Therapeutics, Inc. (RNTX) is not among the 30 most-held stocks of the tracked superinvestor set. Price 0.37 USD; market cap $31.7M.

Price & valuation

Prev Close0.4
Open0.39
Day Range0.32 – 0.41
52 Week Range—
Volume—
Avg Volume (3M)—
Market Cap$31.7MSEC 10-Q, 08/12/2026
BetaVolatility vs the market. Above 1: swings harder than the index.—
P/E (TTM)Price/Earnings: share price over annual profit — what you pay per $1 of earnings. Compare within the sector.LossSEC 10-Q, 06/30/2026
EPS (TTM)Annual net profit per share.-1.72SEC 10-Q, 06/30/2026
Dividend YieldAnnual dividend over share price.0.00%SEC 10-Q, 12/31/2025 · fiscal year

Pro Feature

This section is exclusive to Fundocap Pro. Full holdings tables, consensus trades, ownership analysis, backtests and exports unlock with Pro.

Upgrade to Pro

Frequently Asked Questions

Which superinvestors own RNTX?

Rein Therapeutics, Inc. (RNTX) is not among the 30 most-held stocks of the tracked superinvestor set.

Is institutional sentiment on RNTX bullish or bearish?

RNTX is not among the 30 most-held stocks of the superinvestor set, so net buyer/seller counts are not computed for it.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.